$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000114420416132800 Filed on November 09, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$14.41M	$975.0K	$25.00K
YoY Change	4161.83%	3800.0%
Cost Of Revenue	$430.0K	$41.00K	$0.00
YoY Change
Gross Profit	$12.19M	$934.0K	$25.00K
YoY Change		3636.0%
Gross Profit Margin	84.62%	95.79%	100.0%
Selling, General & Admin	$8.590M	$8.864M	$8.079M
YoY Change	19.14%	9.72%	194.85%
% of Gross Profit	70.47%	949.04%	32316.0%
Research & Development	$10.58M	$7.316M	$9.073M
YoY Change	83.68%	-19.37%	463.89%
% of Gross Profit	86.79%	783.3%	36292.0%
Depreciation & Amortization	$830.0K	$200.0K	$6.000K
YoY Change	8200.0%	3233.33%	0.0%
% of Gross Profit	6.81%	21.41%	24.0%
Operating Expenses	$31.42M	$17.22M	$18.10M
YoY Change	142.44%	-4.84%	316.41%
Operating Profit	-$32.22M	-$17.18M	-$18.10M
YoY Change	148.51%	-5.07%	316.41%
Interest Expense	-$2.000M	$689.0K	$350.0K
YoY Change	-18.37%	96.86%	189.26%
% of Operating Profit
Other Income/Expense, Net		-$710.0K	-$1.783M
YoY Change		-60.18%	624.8%
Pretax Income	-$21.30M	-$16.96M	-$19.86M
YoY Change	41.25%	-14.6%	332.68%
Income Tax
% Of Pretax Income
Net Earnings	-$17.43M	-$12.98M	-$18.16M
YoY Change	44.82%	-28.52%	295.49%
Net Earnings / Revenue	-121.01%	-1331.38%	-72644.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$433.7K	-$323.4K	-$460.8K
COMMON SHARES
Basic Shares Outstanding	48.88M shares	48.67M shares	46.83M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$90.70M	$84.70M	$69.61M
YoY Change	-7.64%	21.68%	-2.78%
Cash & Equivalents	$105.2M	$82.54M	$25.56M
Short-Term Investments	$2.400M	$2.200M	$44.05M
Other Short-Term Assets	$10.10M	$5.600M	$1.100M
YoY Change	531.25%	409.09%	175.0%
Inventory	$203.0K	$123.0K
Prepaid Expenses
Receivables	$1.830M	$5.007M
Other Receivables	$6.900M	$3.200M
Total Short-Term Assets	$109.6M	$98.60M	$66.60M
YoY Change	9.7%	48.05%	-7.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.376M	$1.164M	$100.0K
YoY Change	2287.06%	1064.0%	72.41%
Goodwill	$18.65M	$21.74M
YoY Change
Intangibles
YoY Change
Long-Term Investments	$300.0K	$250.0K	$250.0K
YoY Change	20.0%	0.0%	-16.67%
Other Assets	$394.0K	$48.00K	$14.80M
YoY Change	816.28%	-99.68%	8076.8%
Total Long-Term Assets	$61.10M	$46.82M	$20.26M
YoY Change	227.19%	131.06%	27.17%
TOTAL ASSETS
Total Short-Term Assets	$109.6M	$98.60M	$66.60M
Total Long-Term Assets	$61.10M	$46.82M	$20.26M
Total Assets	$170.7M	$145.4M	$86.86M
YoY Change	43.94%	67.41%	-1.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$24.30M	$21.80M	$1.287M
YoY Change	1200.86%	1593.86%	286.49%
Accrued Expenses	$10.08M	$8.605M	$7.137M
YoY Change	17.64%	20.57%	123.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.000M
YoY Change
Total Short-Term Liabilities	$56.57M	$38.59M	$8.450M
YoY Change	434.69%	356.72%	137.56%
LONG-TERM LIABILITIES
Long-Term Debt	$26.20M	$27.40M	$23.30M
YoY Change	12.93%	17.6%	66.43%
Other Long-Term Liabilities	$5.014M	$4.583M	$202.0K
YoY Change	758.56%	2168.81%	-74.53%
Total Long-Term Liabilities	$5.014M	$4.583M	$202.0K
YoY Change	758.56%	2168.81%	-82.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$56.57M	$38.59M	$8.450M
Total Long-Term Liabilities	$5.014M	$4.583M	$202.0K
Total Liabilities	$87.76M	$70.58M	$31.94M
YoY Change	155.59%	120.96%	70.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$245.3M	-$227.8M	-$178.1M
YoY Change	28.97%	27.9%	29.06%
Common Stock	$49.00K	$49.00K	$47.00K
YoY Change	4.26%	4.26%	6.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$38.50M	$36.63M	$53.60M
YoY Change
Total Liabilities & Shareholders Equity	$170.7M	$145.4M	$86.86M
YoY Change	43.94%	67.41%	-1.3%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$17.43M	-$12.98M	-$18.16M
YoY Change	44.82%	-28.52%	295.49%
Depreciation, Depletion And Amortization	$830.0K	$200.0K	$6.000K
YoY Change	8200.0%	3233.33%	0.0%
Cash From Operating Activities	-$17.97M	-$8.820M	-$15.17M
YoY Change	-728.32%	-41.86%	457.72%
INVESTING ACTIVITIES
Capital Expenditures	-$610.0K	-$1.460M	-$40.00K
YoY Change	221.05%	3550.0%
Acquisitions
YoY Change
Other Investing Activities	-$690.0K	$3.620M	-$11.33M
YoY Change	-102.34%	-131.95%	22560.0%
Cash From Investing Activities	-$1.300M	$2.160M	-$11.37M
YoY Change	-104.44%	-119.0%	22640.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	25.96M	17.86M	11.07M
YoY Change	-35.84%	61.34%	-868.75%
NET CHANGE
Cash From Operating Activities	-17.97M	-8.820M	-15.17M
Cash From Investing Activities	-1.300M	2.160M	-11.37M
Cash From Financing Activities	25.96M	17.86M	11.07M
Net Change In Cash	6.690M	11.20M	-15.47M
YoY Change	-90.79%	-172.4%	267.46%
FREE CASH FLOW
Cash From Operating Activities	-$17.97M	-$8.820M	-$15.17M
Capital Expenditures	-$610.0K	-$1.460M	-$40.00K
Free Cash Flow	-$17.36M	-$7.360M	-$15.13M
YoY Change	-669.18%	-51.35%	456.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	246955000	USD
CY2016Q3	us-gaap	Assets Assets	145421000	USD
CY2015Q4	us-gaap	Assets Assets	118610000	USD
CY2016Q3	us-gaap	Interest Payable Current InterestPayableCurrent	68000	USD
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	27000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	38593000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10579000	USD
CY2016Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	24373000	USD
CY2015Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	23174000	USD
CY2016Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4583000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	584000	USD
CY2016Q3	us-gaap	Liabilities Liabilities	70580000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	34337000	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	49000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	47000	USD
CY2016Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	264397000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-227820000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-190156000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	145421000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118610000	USD
CY2016Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	15859000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	14586000	USD
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	2485000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1550000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1250000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	36626000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	56846000	USD
CY2016Q3	us-gaap	Minority Interest MinorityInterest	38215000	USD
CY2015Q4	us-gaap	Minority Interest MinorityInterest	27427000	USD
CY2016Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	74841000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	18097000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16246000	USD
CY2016Q3	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	3031000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9073000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7316000	USD
CY2016Q3	us-gaap	Long Term Investments LongTermInvestments	685000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3515000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-903000	USD
	us-gaap	Profit Loss ProfitLoss	-49988000	USD
	us-gaap	Profit Loss ProfitLoss	-38808000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2416000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-37664000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-36392000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.94
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.93
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39885685	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39038522	shares
	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-65000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	2072000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	525000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21416000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	3143000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	10882000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14376000	USD
	us-gaap	Operating Expenses OperatingExpenses	49973000	USD
	us-gaap	Operating Expenses OperatingExpenses	38430000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-46473000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-37905000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	241000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	195000	USD
	fbio	Interest Expense And Finance Fees InterestExpenseAndFinanceFees	1838000	USD
	fbio	Interest Expense And Finance Fees InterestExpenseAndFinanceFees	1033000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	105000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2016Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	546000	USD
CY2015Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	25000	USD
CY2016Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1000000	USD
CY2015Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1895000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8864000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7129000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	17180000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18072000	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	89000	USD
CY2016Q3	fbio	Interest Expense And Finance Fees InterestExpenseAndFinanceFees	689000	USD
CY2015Q3	fbio	Interest Expense And Finance Fees InterestExpenseAndFinanceFees	350000	USD
CY2016Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	16000	USD
CY2015Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2016Q3	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-81000	USD
CY2015Q3	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-1472000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1783000	USD
CY2015Q3	us-gaap	Profit Loss ProfitLoss	-19855000	USD
CY2015Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1694000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-12981000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-18161000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40128475	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39412056	shares
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	94000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-27842000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13316000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	84273000	USD
CY2016Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	951000	USD
CY2015Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	114000	USD
CY2016Q3	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	1545000	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	429000	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1793000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	586000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	143000	USD
	us-gaap	Cost Of Goods Sold Amortization CostOfGoodsSoldAmortization	50000	USD
	us-gaap	Cost Of Goods Sold Amortization CostOfGoodsSoldAmortization	0	USD
CY2015Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	156000	USD
CY2016Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5007000	USD
CY2016Q3	us-gaap	Inventory Net InventoryNet	123000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2015Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-12324000	USD
CY2015Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	39000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	41000	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	365000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	975000	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	25000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	3865000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	525000	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	934000	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	25000	USD
	us-gaap	Gross Profit GrossProfit	3500000	USD
	us-gaap	Gross Profit GrossProfit	525000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	240000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17000	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	167000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8792000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11896000	USD
	fbio	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	-48000	USD
	fbio	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	0	USD
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	491000	USD
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	0	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	3095000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	9923000	USD
	us-gaap	Trading Securities Unrealized Holding Gain Loss TradingSecuritiesUnrealizedHoldingGainLoss	0	USD
	us-gaap	Trading Securities Unrealized Holding Gain Loss TradingSecuritiesUnrealizedHoldingGainLoss	11000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	123000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	118000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	1389000	USD
	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	69000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	797000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	325000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5364000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4375000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	41000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-2000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3948000	USD
	fbio	Payment For Research And Development Licenses PaymentForResearchAndDevelopmentLicenses	3095000	USD
	fbio	Payment For Research And Development Licenses PaymentForResearchAndDevelopmentLicenses	9923000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5756000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	350000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1250000	USD
	us-gaap	Payments For Proceeds From Mortgage Deposits PaymentsForProceedsFromMortgageDeposits	5000	USD
	us-gaap	Payments For Proceeds From Mortgage Deposits PaymentsForProceedsFromMortgageDeposits	0	USD
	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	175000	USD
	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	130000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4755000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-31335000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	216000	USD
	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	81000	USD
	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	26000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	13016000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	12575000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	49000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2792000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	0	USD
	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	10000000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	855000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3018000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	392000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	16952000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	20455000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-15645000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-24196000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49759000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25563000	USD
	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	434000	USD
	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	0	USD
CY2016Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	15500000	USD
CY2016Q3	us-gaap	Notes Payable NotesPayable	14900000	USD
	fbio	Percentage Of Tax Benefit Likely Of Being Realized PercentageOfTaxBenefitLikelyOfBeingRealized	0.5	pure
CY2016Q3	us-gaap	Depreciation Depreciation	154000	USD
CY2015Q3	us-gaap	Depreciation Depreciation	6000	USD
	us-gaap	Depreciation Depreciation	240000	USD
	us-gaap	Depreciation Depreciation	17000	USD
CY2014Q1	us-gaap	Equity Method Investments EquityMethodInvestments	250000	USD
CY2014Q1	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.35	pure
CY2016Q3	us-gaap	Equity Method Investments EquityMethodInvestments	250000	USD
	us-gaap	Investments In And Advances To Affiliates At Fair Value Period Increase Decrease InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease	1800000	USD
	fbio	Percentage Of Outstanding Stock To Be Issued Upon Exercise Of Warrants PercentageOfOutstandingStockToBeIssuedUponExerciseOfWarrants	0.25	pure
CY2016Q3	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	685000	USD
CY2015Q4	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	2485000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-65000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	4160000	USD
CY2015Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	4095000	USD
CY2015Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	2599000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	5928000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-1800000	USD
CY2016Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	6845000	USD
CY2016Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1244000	USD
CY2015Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	950000	USD
CY2015Q3	us-gaap	Assets Assets	86864000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4212000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1632000	USD
CY2015Q3	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	66000	USD
CY2016Q3	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	0	USD
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	84000	USD
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	154000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1065501	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.37
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.73
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.77
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M25D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y2M5D
	fbio	Lease Sharing Agreements Contributions To Property Under Lease LeaseSharingAgreementsContributionsToPropertyUnderLease	4700000	USD
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	8792000	USD
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	11896000	USD
CY2016Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2903000	USD
CY2015Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	8501000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1779365	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1130501	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y29D
	fbio	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue	0	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	710269	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.51
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	648864	shares
	fbio	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue	0	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	666396	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	745069	USD
CY2016Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	16000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2M19D
CY2016Q3	fbio	Employee Stock Purchase Plan Offering Fair Value Reckoning Percentage EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage	0.85	pure
CY2015Q3	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	13000	USD
	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	28000	USD
CY2016Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10000	shares
CY2016Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	53000000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13767873	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9757654	shares
CY2015	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	32882000	USD
CY2015	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5455000	USD
CY2016Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1777000	USD
CY2015Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2492000	USD
CY2016Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1389000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	382000	USD
CY2016Q3	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	788000	USD
CY2015Q4	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	810000	USD
CY2016Q3	fbio	Other Short Term Liabilities Related To Manufacturing Rights OtherShortTermLiabilitiesRelatedToManufacturingRights	750000	USD
CY2015Q4	fbio	Other Short Term Liabilities Related To Manufacturing Rights OtherShortTermLiabilitiesRelatedToManufacturingRights	1500000	USD
CY2016Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	703000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	523000	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8605000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8570000	USD
CY2016Q3	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	2802000	USD
CY2015Q4	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	2717000	USD
CY2016Q3	fbio	Accrued Cost Of Good Sold AccruedCostOfGoodSold	301000	USD
CY2015Q4	fbio	Accrued Cost Of Good Sold AccruedCostOfGoodSold	0	USD
CY2016Q3	fbio	Lease Impairment Current LeaseImpairmentCurrent	95000	USD
CY2015Q4	fbio	Lease Impairment Current LeaseImpairmentCurrent	146000	USD
CY2016Q3	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	4583000	USD
CY2015Q4	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	584000	USD
CY2016Q3	us-gaap	Long Term Debt LongTermDebt	30168000	USD
CY2016Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14029000	USD
CY2015Q4	us-gaap	Long Term Debt LongTermDebt	24009000	USD
CY2015Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	835000	USD
CY2016Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	2800000	USD
	us-gaap	Interest Expense InterestExpense	1838000	USD
	us-gaap	Interest Expense InterestExpense	1033000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	689000	USD
CY2016Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	21831000	USD
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10438000	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	350000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	Fortress Biotech, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001429260
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	FBIO
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48875087	shares
CY2016Q3	us-gaap	Deposits With Clearing Organizations And Others Securities DepositsWithClearingOrganizationsAndOthersSecurities	1030000	USD
CY2015Q4	us-gaap	Deposits With Clearing Organizations And Others Securities DepositsWithClearingOrganizationsAndOthersSecurities	0	USD
CY2016Q3	us-gaap	Receivables From Brokers Dealers And Clearing Organizations ReceivablesFromBrokersDealersAndClearingOrganizations	1607000	USD
CY2015Q4	us-gaap	Receivables From Brokers Dealers And Clearing Organizations ReceivablesFromBrokersDealersAndClearingOrganizations	0	USD
CY2016Q3	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	2178000	USD
CY2015Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	0	USD
CY2016Q3	us-gaap	Goodwill Goodwill	21739000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	0	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	0	USD
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	48000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	43000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	81000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived and intangible assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, derivative warrant liabilities, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47147032	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47147032	shares
	fbio	Stock Cancelled During Period Value Restricted Stock Award StockCancelledDuringPeriodValueRestrictedStockAward	0	USD
CY2016Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2764000	USD
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48875087	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48875087	shares
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2016Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.3949	pure
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	8792000	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	11652000	USD
	fbio	Issuance Of Common Stock For At Market Offering IssuanceOfCommonStockForAtMarketOffering	434000	USD
	fbio	Adjustments To Additional Paid In Capital Stock Issued For License Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses	48000	USD
	fbio	Stock Issued During Period Valuecashless Exercise Of Warrants StockIssuedDuringPeriodValuecashlessExerciseOfWarrants	0	USD
	fbio	Adjustments To Additional Paid In Capital At Market Offering Costs AdjustmentsToAdditionalPaidInCapitalAtMarketOfferingCosts	-49000	USD
CY2016Q3	fbio	Change In Fair Value Of Subsidiary Convertible Note ChangeInFairValueOfSubsidiaryConvertibleNote	-13000	USD
	fbio	Change In Fair Value Of Subsidiary Convertible Note ChangeInFairValueOfSubsidiaryConvertibleNote	-13000	USD
	fbio	Change In Fair Value Of Subsidiary Convertible Note ChangeInFairValueOfSubsidiaryConvertibleNote	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-4626000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	19938000	USD
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	1364000	USD
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	1507000	USD
	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	5000000	USD
	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	920000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	920000	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	1881000	USD
	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	0	USD
	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	17717000	USD
CY2016Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	27498000	USD
CY2016Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	4889000	USD
CY2016Q3	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash Deposites With Clearing Organizations BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashDepositesWithClearingOrganizations	1030000	USD
CY2016Q3	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Receivable From Brokersdealers And Clearing Agencies BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivableFromBrokersdealersAndClearingAgencies	1607000	USD
CY2016Q3	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Securities Owned Fair Value BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSecuritiesOwnedFairValue	2178000	USD
CY2016Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	1985000	USD
CY2016Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	1132000	USD
CY2016Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	353000	USD
CY2016Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	62411000	USD
CY2016Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	6079000	USD
CY2016Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	21822000	USD
CY2016Q3	us-gaap	Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue	17717000	USD
CY2016Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Less Noncontrolling Interest BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest	22872000	USD
CY2016Q3	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Clearing And Marketing Credits BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredClearingAndMarketingCredits	1007000	USD
CY2016Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.09	pure
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1132000	USD
CY2016Q3	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	3982000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	13000	USD
	fbio	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisDerivativeLiabilityGainLossIncludedInEarnings	105000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	28000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2016Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	54000	USD
CY2015Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	0	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	54000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	0	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1462000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1298000	USD
	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	50539000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	3015000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2253000	USD
CY2016Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	26000	USD
CY2015Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	26000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2016Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	28000	USD
CY2015Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Interest Paid InterestPaid	238000	USD
	us-gaap	Interest Paid InterestPaid	80000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1004000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	634000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	2062000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	11094000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Receivable Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsReceivableRemainderOfFiscalYear	84000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Receivable In Two Years OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears	0	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Receivable In Three Years OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears	0	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Receivable In Four Years OperatingLeasesFutureMinimumPaymentsReceivableInFourYears	0	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Receivable In Five Years OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears	0	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Receivable Thereafter OperatingLeasesFutureMinimumPaymentsReceivableThereafter	0	USD
	fbio	Non Cash Or Part Noncash Acquisition Beneficial Conversion Feature Related To Opus Credit Facility NonCashOrPartNoncashAcquisitionBeneficialConversionFeatureRelatedToOpusCreditFacility	1881000	USD
	fbio	Non Cash Or Part Noncash Acquisition Beneficial Conversion Feature Related To Opus Credit Facility NonCashOrPartNoncashAcquisitionBeneficialConversionFeatureRelatedToOpusCreditFacility	0	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Receivable OperatingLeasesFutureMinimumPaymentsReceivable	84000	USD
CY2016Q3	fbio	Operating Leases Future Minimum Payments Remainder Of Fiscal Year Net Of Sublease Income OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYearNetOfSubleaseIncome	2931000	USD
CY2016Q3	fbio	Operating Leases Future Minimum Payments Due In Two Years Net Of Sublease Income OperatingLeasesFutureMinimumPaymentsDueInTwoYearsNetOfSubleaseIncome	2253000	USD
CY2016Q3	fbio	Operating Leases Future Minimum Payments Due In Three Years Net Of Sublease Income OperatingLeasesFutureMinimumPaymentsDueInThreeYearsNetOfSubleaseIncome	1462000	USD
CY2016Q3	fbio	Operating Leases Future Minimum Payments Due In Four Years Net Of Sublease Income OperatingLeasesFutureMinimumPaymentsDueInFourYearsNetOfSubleaseIncome	1298000	USD
CY2016Q3	fbio	Operating Leases Future Minimum Payments Due In Five Years Net Of Sublease Income OperatingLeasesFutureMinimumPaymentsDueInFiveYearsNetOfSubleaseIncome	1004000	USD
CY2016Q3	fbio	Operating Leases Future Minimum Payments Due Thereafter Net Of Sublease Inocome OperatingLeasesFutureMinimumPaymentsDueThereafterNetOfSubleaseInocome	2062000	USD
CY2016Q3	fbio	Operating Leases Future Minimum Payments Due Net Of Sublease Income OperatingLeasesFutureMinimumPaymentsDueNetOfSubleaseIncome	11010000	USD
	fbio	Non Cash Or Part Noncash Acquisition Goodwill NonCashOrPartNoncashAcquisitionGoodwill	-21739000	USD
	fbio	Non Cash Or Part Noncash Acquisition Goodwill NonCashOrPartNoncashAcquisitionGoodwill	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1 NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1	-4889000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1 NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1	0	USD
	fbio	Noncash Or Part Noncash Acquisition Cash Deposits With Claening Organisations NoncashOrPartNoncashAcquisitionCashDepositsWithClaeningOrganisations	-1030000	USD
	fbio	Noncash Or Part Noncash Acquisition Cash Deposits With Claening Organisations NoncashOrPartNoncashAcquisitionCashDepositsWithClaeningOrganisations	0	USD
	fbio	Noncash Or Part Noncash Acquisition Receivables From Brokerdealers And Clearing Organizations NoncashOrPartNoncashAcquisitionReceivablesFromBrokerdealersAndClearingOrganizations	-1607000	USD
	fbio	Noncash Or Part Noncash Acquisition Receivables From Brokerdealers And Clearing Organizations NoncashOrPartNoncashAcquisitionReceivablesFromBrokerdealersAndClearingOrganizations	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Investments Acquired1 NoncashOrPartNoncashAcquisitionInvestmentsAcquired1	-2178000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Investments Acquired1 NoncashOrPartNoncashAcquisitionInvestmentsAcquired1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	-1985000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	-1132000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
	fbio	Non Cash Or Part Noncash Acquisition Restricted Cash NonCashOrPartNoncashAcquisitionRestrictedCash	-353000	USD
	fbio	Non Cash Or Part Noncash Acquisition Restricted Cash NonCashOrPartNoncashAcquisitionRestrictedCash	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	-6079000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Employee Benefit Liabilities Assumed1 NoncashOrPartNoncashAcquisitionEmployeeBenefitLiabilitiesAssumed1	-14029000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Employee Benefit Liabilities Assumed1 NoncashOrPartNoncashAcquisitionEmployeeBenefitLiabilitiesAssumed1	0	USD
	fbio	Non Cash Or Part Noncash Acquisition Non Controlling Interests NonCashOrPartNoncashAcquisitionNonControllingInterests	17717000	USD
	fbio	Non Cash Or Part Noncash Acquisition Non Controlling Interests NonCashOrPartNoncashAcquisitionNonControllingInterests	0	USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	fbio	Change In Fair Value Of Subsidiary Convertible Note ChangeInFairValueOfSubsidiaryConvertibleNote	0	USD
CY2015Q1	fbio	Agreement Description Terms AgreementDescriptionTerms	(i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Mustang or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when the Company no longer has majority voting control in Mustang’s voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of Mustang’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control, Mustang will pay a one-time change in control fee equal to five (5x) times the product of (A) monthly net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%).
CY2016Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	47317000	USD
CY2015Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	42360000	USD
CY2016Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-12962000	USD
CY2016Q3	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-0.32
CY2015Q1	fbio	Agreement Description Terms AgreementDescriptionTerms	(i) issue annually to the Company, on the anniversary date of the Founders Agreement, shares of common stock equal to two and one half percent (2.5%) of the fully-diluted outstanding equity of Helocyte at the time of issuance; (ii) pay an equity fee in shares of Helocyte common stock, payable within five (5) business days of the closing of any equity or debt financing for Helocyte or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when Fortress no longer has majority voting control in Helocyte’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of Helocyte’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) monthly net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).
CY2015Q1	fbio	Agreement Description Terms AgreementDescriptionTerms	(i) issue annually to the Company, on the anniversary date of the Founders Agreement, shares of common stock equal to 2.5%  of the fully-diluted outstanding equity of Checkpoint at the time of issuance; (ii) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Checkpoint or any of its subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when the Company no longer has majority voting control in Checkpoint’s voting equity, equal to 2.5% of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to 4.5% of Checkpoint’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), Checkpoint will pay a one-time change in control fee equal to five times (5x) the product of (i) net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).
CY2015Q1	fbio	Agreement Description Terms AgreementDescriptionTerms	(i) issue annually to the Company, on the anniversary date of the Founders Agreement, shares of common stock equal to two and one half percent (2.5%) of the fully-diluted outstanding equity of Avenue at the time of issuance; (ii) pay an equity fee in shares of Avenue common stock, payable within five (5) business days of the closing of any equity or debt financing for Avenue or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when Fortress no longer has majority voting control in Avenue’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of Avenue’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) monthly net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	4626000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
	fbio	Cash And Cash Equivalents Acquired From Business Combination CashAndCashEquivalentsAcquiredFromBusinessCombination	27498000	USD
	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	22872000	USD
CY2016Q3	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	30000	USD
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	33958	shares
CY2016Q3	fbio	Class Of Warrant Or Right Discount On Warrant ClassOfWarrantOrRightDiscountOnWarrant	1.9	USD
CY2015Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-17797000	USD
CY2016Q3	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.32
CY2015Q3	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-0.45
CY2016Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2016Q3	us-gaap	Contractual Obligation ContractualObligation	1900000	USD
CY2016Q3	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	1100000	USD
CY2016Q3	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	800000	USD
CY2016Q3	us-gaap	Deferred Revenue And Credits Current DeferredRevenueAndCreditsCurrent	1007000	USD
CY2015Q4	us-gaap	Deferred Revenue And Credits Current DeferredRevenueAndCreditsCurrent	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	-707000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	0	USD
	fbio	Noncash Or Part Noncash Acquisition Deferred Clearing And Marketing Credits Assumed NoncashOrPartNoncashAcquisitionDeferredClearingAndMarketingCreditsAssumed	0	USD
	fbio	Noncash Or Part Noncash Acquisition Deferred Clearing And Marketing Credits Assumed NoncashOrPartNoncashAcquisitionDeferredClearingAndMarketingCreditsAssumed	-1007000	USD
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13644367	shares
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10154952	shares
CY2016Q3	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Compensation Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationPayable	14029000	USD
CY2016Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	707000	USD
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	126976000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-34985000	USD
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.90
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-0.90
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	131862000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-37355000	USD
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.94
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-0.94
CY2015Q4	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	200000	USD
CY2015Q3	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.45
	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	56000	USD
CY2016Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	707000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	USD

Files In Submission

Name	View Source	Status
0001144204-16-132800-index-headers.html	Edgar Link	pending
0001144204-16-132800-index.html	Edgar Link	pending
0001144204-16-132800.txt	Edgar Link	pending
0001144204-16-132800-xbrl.zip	Edgar Link	pending
fbio-20160930.xml	Edgar Link	completed
fbio-20160930.xsd	Edgar Link	pending
fbio-20160930_cal.xml	Edgar Link	unprocessable
fbio-20160930_def.xml	Edgar Link	unprocessable
fbio-20160930_lab.xml	Edgar Link	unprocessable
fbio-20160930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v449362_10q.htm	Edgar Link	pending
v449362_ex10-33.htm	Edgar Link	pending
v449362_ex10-34.htm	Edgar Link	pending
v449362_ex10-35.htm	Edgar Link	pending
v449362_ex10-36.htm	Edgar Link	pending
v449362_ex31-1.htm	Edgar Link	pending
v449362_ex31-2.htm	Edgar Link	pending
v449362_ex32-1.htm	Edgar Link	pending
v449362_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2016 Q4 Form 10-Q Financial Statement

#000114420416132800 Filed on November 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2016 Q4 Form 10-Q Financial Statement

#000114420416132800 Filed on November 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio